Reduced-Dose CHOP Therapy for Elderly Patients with Non-Hodgkin's Lymphoma

References

• Simon R., Durrleman S., Hopper R. T., Bonadonna G., Bloomfield C. D., Rudders R. A., Cheson B. D., Berard C. W. Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphoma: experience of the non-Hodgkin's lymphoma pathologic classification project. Medical and Pediatric Oncology 1990; 18: 89–96, 89
   PubMedGoogle Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factor Project. A predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine 1993; 32: 987–994
   Google Scholar
• Fisher R. I., Gaynor E. R., Dahlberg S., Oken M. M., Groga T. M., Mize E. M., Glick J. H., Coltman C. A., Jr., Miller T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non Hodgkin's lymphoma. New England Journal of Medicine 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Mori M., Murai Y., Suzuki K., Nonaka Y., Sato H., Tomiyama J., Takagi T., Muto Y., Kashimura M. Study of optimal CHOP dose ranges for elderly patients with non-Hodgkin's lymphoma. Japan Journal of Clinical Hematology (in Japanese) 1999; 40(3)199–204
   PubMedGoogle Scholar
• National Cancer Institute-sponsored study of classification of non-Hodgkin's lymphoma. Summary and description of a Working Formulation for clinical usage. Cancer 1982; 49: 2112–2135
   PubMed Web of Science ®Google Scholar
• Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkin's disease staging classification. Cancer Research 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Hryniuk W. M. The importance of dose intensity in the outcome of chemotherapy. Important advances in oncology 1988; 121–141
   PubMedGoogle Scholar
• Armitage J. O., Potter J. P. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly: Increased complications with advancing age. Journal of American Geriatrics 1984; 32: 269–273
   PubMed Web of Science ®Google Scholar
• Dixon D. O., Neilan B., Jones S. E., Lipschitz D. A., Miller T. P., Grozea P. N., Wilson H. E. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. Journal of Clinical Oncology 1986; 4: 295–305
   PubMed Web of Science ®Google Scholar
• d'Amore F., Brincker H., Christensen B. E., Thorling K., Pedersen M., Nielsen J. L., Sandberg E., Pedersen N. T., Sorensen E. Non-Hodgkin's lymphoma in the elderly. A study of 602 patients aged 70 or older from a Danish population-based registry. Annals of Oncology 1992; 3: 379–386
   PubMed Web of Science ®Google Scholar
• Tirelli U., Zagonel V., Serrano D., Thomas J., Hoerni B., Tangury A., Rruhl U., Bey P., Tubiana N., Breed W. P. Non-Hodgkin's lymphoma in 137 patients aged 70 years or older: a retrospective European Organization for Research and Treatment of Cancer Lymphoma Group study. Journal of Clinical Oncology 1998; 6: 1708–1713
   Google Scholar
• Miller T. P., Jones S. E. Initial chemotherapy for clinically localized lymphoma of unfavorable histology. Blood 1983; 62: 413–418
   PubMed Web of Science ®Google Scholar
• Meyer R. M., Hryniuk W. M., Goodyear M. D. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. Journal of Clinical Oncology 1991; 9: 339–347
   PubMed Web of Science ®Google Scholar
• Kwak L. W., Halpern J., Olshen R. A., Horning S. J. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. Journal of Clinical Oncology 1990; 8: 963–977
   PubMed Web of Science ®Google Scholar
• Sonneveld P., de Ridder M., van der Lelie H., Nieuwenhuis K., Schouten H., Mulder A., van Reijswoud I., Hop W., Lowenberg B. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. Journal of Clinical Oncology 1995; 13: 2530–2539
   PubMed Web of Science ®Google Scholar
• Epelbaum R., Haim N., Leviov M., Ben-Shahar M., Ben-Arie Y., Dror Y. Full dose CHOP chemotherapy in elderly patients with non-Hodgkin's lymphoma. Acta Oncologica 1995; 34: 87–91
   PubMed Web of Science ®Google Scholar
• Gomez H., Mas L., Casanova L., Pen D. L. K., Santillana S., Valdivia S., Otero J., Rodriguez W., Carracedo C., Vallejos C. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity. Journal of Clinical Oncology 1998; 16: 2352–2358
   PubMed Web of Science ®Google Scholar
• Tirelli U., Zagonel V., Errante D., Serraino D., Talamini R., De Cicco M., Carbone A., Monfardini S. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. Journal of Clinical Oncology 1992; 10: 228–236
   PubMed Web of Science ®Google Scholar
• Zinzani P. L., Storti S., Zaccaria A., Moretti L., Magagnoli M., Pavone E., Gentilini P., Guardigni L., Gobbi M., Fattori P. P., Falini B., Lauta V. M., Bendandi M., Gherlinzoni F., Renzo A. D., Zaja F., Mazza P., Volpe E., Bocchia M., Aitini E., Tabanelli M., Leone G., Tura S. Elderly aggressive-history non-Hodgkin's lymphoma: first line VENCOP-B regimen experience in 350 patients. Blood 1999; 94: 33–38
   PubMed Web of Science ®Google Scholar